DelveInsight Estimates a Promising Picture of JAK Inhibitors Clinical Trial Pipeline Landscape in the Coming Years as 40+ Key Pharma Players Bolster the Treatment Space

News provided by

Nov 15, 2022, 10:30 ET

JAK inhibitors clinical trial pipeline constitutes 40+ key companies continuously working towards developing 45+ JAK inhibitor drugs, analyzes DelveInsight

LAS VEGAS, Nov. 15, 2022 /PRNewswire/ -- DelveInsight's 'JAK Inhibitors Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline JAK inhibitor drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors competitive domain.

Key Takeaways from the JAK Inhibitors Pipeline Report

Over 40+ JAK Inhibitors companies are evaluating 45+ JAK inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the JAK inhibitors market would significantly increase market revenue.
Leading JAK inhibitor companies such as Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, Geron Corporation, R-Pharm, Almedis LLC, ScienceFiles, Vertex Pharmaceuticals Incorporated, Italfarmaco, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Bristol-Myers Squibb, Cephalon, Karyopharm Therapeutics Inc, and others are evaluating novel JAK inhibitor drugs candidate to improve the treatment landscape.
Key JAK inhibitor pipeline therapies in various stages of development include PF-06651600, Momelotinib, TD-8236, DZD4205, TD-0903, TD-5202, ATI-2138, CPL409116, Itacitinib, Ruxolitinib, Upadacitinib, Filgotinib, Ivarmacitinib, and others.
In October 2022, AbbVie announced that the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) had been approved by the US Food and Drug Administration (FDA) for adults with non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation and have had an inadequate response to or are intolerant of one or more tumor necrosis factor (TNF) inhibitors.
In October 2022, Incyte announced that data from the pivotal Phase III TRuE-V clinical trial program evaluating ruxolitinib cream (OpzeluraTM) 1.5% in patients 12 years of age and older with nonsegmental vitiligo had been published in "The New England Journal of Medicine (NEJM)."
In September 2022, -Bristol Myers Squibb announced new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating clinical efficacy was maintained with continuous Sotyktu™ (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. This analysis assessed patients from the pivotal POETYK PSO-1 trial who transitioned into the LTE trial. At 112 weeks of Sotyktu treatment, modified non-responder imputation (mNRI) response rates were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90 and 66.5% for static Physician's Global Assessment (sPGA) 0/1.
In July 2022, AbbVie announced that it had submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.
In March 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) had approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for RINVOQ in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies.
In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) had approved RINVOQ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when the use of other pills or injections is not recommended.

Request a sample and discover the recent advances in the JAK inhibitors market @JAK Inhibitors Competitive Landscape Report

JAK Inhibitors Overview

Janus kinase (JAK) inhibitors are small molecules of about 400 Da that can be administered orally. JAKs are phosphotransferases that bind to cytokine receptor intracellular domains and transmit signals to activate immune responses. Many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines are among the cytokines that signal via JAKs (such as erythropoietin). These cytokine receptors communicate via various combinations of four JAKs (JAK1, JAK2, JAK3, and TYK2).

Tofacitinib and baricitinib (and oclacitinib in dogs) are first-generation jakinibs that block more than one JAK and thus inhibit many cytokines; these and other pan-jakinibs are being studied as therapeutic agents for a wide range of autoimmune diseases.

Several JAK inhibitor clinical trials are currently underway, ranging from cancer to autoimmune diseases like psoriasis. Several other JAK inhibitors may be effective in the treatment of multiple disorders in the future.

Find out more about FDA JAK inhibitors @JAK Inhibitor Drugs List

JAK Inhibitors Pipeline Analysis: Drug Profile

RINVOQ: AbbVie

RINVOQ, a selective JAK inhibitor discovered and developed by AbbVie scientists, is being studied in a variety of immune-mediated inflammatory diseases. RINVOQ inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy and safety is unknown at this time.

RINVOQ is currently being studied in phase III trials for colitis, giant cell arteritis, and Takayasu arteritis.

Filgotinib: Galapagos

Galapagos' Filgotinib (200 mg and 100 mg tablets) is approved and marketed in Europe and Japan for the treatment of adults with moderately to severely active RA who have not responded adequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib can be used alone or in conjunction with methotrexate (MTX). Filgotinib was submitted to the European Commission for an expanded indication for the treatment of adults with moderate to severe active ulcerative colitis who had an inadequate response, lost response to, or were intolerant to, conventional therapy or a biologic agent.

A snapshot of the JAK Inhibitors Pipeline Drugs mentioned in the report:

JAK Inhibitors Drugs	Company	Phase	Indication
RINVOQ	AbbVie	Pre-registration	Crohn's disease
Ritlecitinib	Pfizer	Pre-registration	Alopecia areata
Momelotinib	Sierra Oncology	Pre-registration	Myelofibrosis
Ruxolitinib	Incyte Corporation/Novartis	Phase III	Cytokine release syndrome; Essential thrombocythaemia; SARS-CoV-2 acute respiratory disease
Filgotinib	Galapagos	Phase III	Crohn's disease
Itacitinib	Incyte Corporation	Phase III	Graft-versus-host disease
Ivarmacitinib	Arcutis Biotherapeutics/Reistone Biopharma	Phase III	Atopic dermatitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Golidocitinib	Dizal Pharmaceutical	Phase II	Peripheral T-cell lymphoma
Nezulcitinib	Theravance Biopharma	Phase II	Acute lung injury
CPL409116	Celon Pharma	Phase II	Rheumatoid arthritis
TD 5202	Theravance Biopharma	Phase I	Inflammatory bowel diseases
ATI-2138	Aclaris Therapeutics	Phase I	Psoriasis

Learn more about the JAK inhibitor drugs @JAK Inhibitor Trials

Scope of the JAK Inhibitors Competitive Landscape Report

Coverage: Global
Key JAK Inhibitors Companies: Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, Geron Corporation, R-Pharm, Almedis LLC, ScienceFiles, Vertex Pharmaceuticals Incorporated, Italfarmaco, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Bristol-Myers Squibb, Cephalon, Karyopharm Therapeutics Inc, and others
Key JAK Inhibitors Pipeline Therapies: PF-06651600, Momelotinib, TD-8236, DZD4205, TD-0903, TD-5202, ATI-2138, CPL409116, Itacitinib, Ruxolitinib, Upadacitinib, Filgotinib, Ivarmacitinib, and others.

Dive deep for rich insights into JAK inhibitor therapy; visit @FDA-approved JAK Inhibitors

Table of Contents

1.	JAK Inhibitors Pipeline Report Introduction
2.	JAK Inhibitors Pipeline Report Executive Summary
3.	JAK Inhibitors Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	JAK Inhibitors Clinical Trial Therapeutics
6.	JAK Inhibitors Pipeline: Late Stage Products (Pre-registration)
7.	JAK Inhibitors Pipeline: Late Stage Products (Phase III)
8.	JAK Inhibitors Pipeline: Mid Stage Products (Phase II)
9.	JAK Inhibitors Pipeline: Early Stage Products (Phase I)
10.	JAK Inhibitors Pipeline Therapeutic Assessment
11.	Inactive Products in the JAK Inhibitors Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the JAK Inhibitors Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the JAK inhibitors therapeutics assessment, reach out @JAK Inhibitor Therapy

Related Reports

Graft vs. Host Disease Market

Graft vs. Host Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key graft vs. host disease companies including ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, among others.

Graft vs. Host Disease Epidemiology Forecast

Graft vs. Host Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted graft vs. host disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Graft vs. Host Disease Pipeline

Graft vs. Host Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key graft vs. host disease companies, including Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, among others.

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including Abivax, UCB, Sierra Oncology, Taisho, among others.

Myelofibrosis Pipeline

Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.

Myelofibrosis Market

Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.

Other Trending Reports